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Due to their low self-repair ability, cartilage defects that result from joint injury, aging, or osteoarthritis, are the most often
irreversible and are a major cause of joint pain and chronic disability. So, in recent years, researchers and surgeons have been
working hard to elaborate cartilage repair interventions for patients who suffer from cartilage damage. However, current methods
do not perfectly restore hyaline cartilage and may lead to the apparition of fibro- or hypertrophic cartilage. In the next years, the
development of new strategies using adult stem cells, in scaffolds, with supplementation of culture medium and/or culture in low
oxygen tension should improve the quality of neoformed cartilage. Through these solutions, some of the latest technologies start
to bring very promising results in repairing cartilage from traumatic injury or chondropathies. This review discusses the current
knowledge about the use of adult stem cells in the context of cartilage tissue engineering and presents clinical trials in progress, as
well as in the future, especially in the field of bioprinting stem cells.
1. Cartilage, a Tissue with Low
Capacity of Repair
Articular cartilage is a stable tissue that functions for decades
to keep normal joint movement possible. It is a hyaline
tissue with no blood, lymphatic or nerve supply. It contains
a single type of cells, called chondrocytes (cell density:
1,500 to 2,000/mm3), maintained in an abundant connective
tissue (Figure 1). This highly hydrated extracellular matrix
(70–80%) is composed of collagen fibers, mainly type II
collagen, and proteoglycan aggregates, mainly aggrecan,
attached along a filament of hyaluronic acid. Collagens
provide tensile strength, while proteoglycans are responsible
for the compressive strength. The whole forms a viscoelastic
structure well suited for both functions of cartilage: the
absorption and distribution of forces and the sliding of the
joint surfaces with a very low coefficient of friction. Thus,
cartilage protects the subchondral bone acting as a lubricant
and a shock absorber [1, 2]. Chondrocytes are responsible for
the synthesis of this matrix. Indeed, these cells respond to
growth factors, cytokines, or joint loading, by synthesizing
extracellular matrix molecules. At opposite, chondrocytes
can also express enzymes such as metalloproteases, favoring
cartilage turnover and renewal.
During life, articular cartilage defects may happen and
form areas of damaged or missing cartilage.These defects are
often caused by acute trauma. Biochemical changes due to age
may also stimulate the degradation of cartilage matrix and
at term lead to chronic diseases such as osteoarthritis. These
defects are themost often irreversible, since articular cartilage
has very limited self-repair capability. This is partially due
to its avascularity. With the lack of blood supply, a set
of complex biochemical events that take place in order to
repair the damage fails to occur. In addition, wound healing
in hyaline cartilage is prevented by the dense extracellular
matrix, which impairs the migration of chondrocytes [3–5].
However, a repair processmay be initiated by undifferentiated
mesenchymal stem cells (MSCs) from the bonemarrow tissue
of subchondral bone [6, 7]. Small full thickness defects can
be repaired by formation of hyaline cartilage, whereas large
osteochondral defects are only repaired by formation of scar
tissue (fibrous tissue) or fibrocartilage. This fibrocartilage is
Hindawi Publishing Corporation
Stem Cells International
Article ID 438026
2 Stem Cells International
Muscle
Cartilage
Synovial 
liquid
Ligament
Bone
Synovial 
membrane
Chondrocytes
Figure 1: An overview of a typical joint structure. Hyaline cartilage,
the most common type of cartilage, is located at the extremity
of bones. It protects the subchondral bone acting as a lubricant
and a shock absorber. It contains a single type of cells, called
chondrocytes, maintained in an abundant matrix rich in collagen
and proteoglycans.
a poorly organized tissue containing significant amounts of
collagen type I. It exhibits inferior mechanical and biochem-
ical characteristics compared to normal hyaline articular
cartilage. The matrix of fibrocartilage breaks down with time
and loading, leading to development of secondary OA in
injured cartilage.
Consequently, when damaged, cartilage repair and regen-
eration is a major challenge. Currently, therapies such as
microfracture, abrasion, drilling, and osteochondral grafting
are applied and help to reduce pain to some degree. However,
complications and injuries are huge and the results are
largely unsatisfactory. In this context, regenerative cartilage
medicine has been developing since 1987, with the first trans-
plantation of autologous chondrocytes [8].More recently, cell
therapies based on adult stem cells have emerged.
2. Cartilage Tissue Engineering by
Autologous Cell Implantation
Cartilage is an attractive candidate for use in tissue-engi-
neering therapies since this tissue is avascular and has a
limited capacity for repair. With regard to chondrocyte
implantation, an autologous strategy is preferred because
of the risks associated with allogenic strategies, such as
triggering an immunogenic response or transferring diseases.
Autologous chondrocyte implantation (ACI) procedures take
place in three stages (Figure 2). First, chondrocytes are
extracted arthroscopically from the patient’s healthy articular
cartilage (nonload-bearing area of either the intercondylar
notch or the superior ridge of the femoral condyles). Then,
chondrocytes are expanded in vitro for approximately four
to six weeks. Finally, once a sufficient number of cells have
been obtained, the patient undergoes a second surgery where
the cultured and amplified chondrocytes are applied to the
damaged area. These transplanted cells grow in their new
environment, forming new articular cartilage [9].
The use of autologous chondrocyte implantation may
represent a promising technology for cartilage repair in
orthopedic research. However, we and other investigators
have established that, during monolayer expansion of chon-
drocytes in vitro, this cell population loses its phenotype, as
illustrated by a switch in collagen production from type II
(typical of hyaline cartilage) toward types I and III (typical of
fibrocartilage) [10–12].The result of these phenotype changes
is the production of an extracellular matrix with inferior
biomechanical properties. In addition, the limited capacity
of the donor site to provide a large amount of chondrocytes,
as well as donor site morbidity, is major obstacles for auto-
logous chondrocytes. Therefore, use of stem cells, such as
mesenchymal stem cells (MSCs), may be preferred. MSCs
can be relatively easily harvested and the procedures using
them are less invasive or destructive than articular cartilage
harvesting procedures.
3. Sources of Mesenchymal Stem
Cells for Cartilage Engineering
Mesenchymal stem cells (MSCs) have been heralded as the
next major development in the repair and regeneration of
cartilage. They are considered as an appropriate candidate
owing to several specific characteristics (inherent chondro-
genic property, easy availability, and cell homing potential).
However, their use is still limited, with only 16% of reported
cell therapy procedures for cartilage repair using MSCs, with
the remaining chondrocytes [13].
3.1. Bone Marrow MSCs. MSCs, as nonhematopoietic cells,
are originally derived from bone marrow tissue. In the 60s,
scientists found that marrow cells are able to produce carti-
lage and bone-like tissue in vivo [14], but they were unable
to determine the cells responsible for this property. Then,
a fibroblastic population was isolated and described as the
cellular equivalent of chondrogenic and osteogenic features
of marrow tissue. Initially referred to as colony forming unit
fibroblasts, these cells are now called mesenchymal stem cells
(MSCs).
MSCs possess two important properties, long-term self-
renewal ability and the capacity to differentiate alongmultiple
cell lineages, such as bone, cartilage, and adipose cells. In
spite of their limited numbers in bone marrow aspirate (the
frequency of MSCs in the whole bone marrow of skeletally
mature adults ranges from 1 in 50 000 to 1 in 100 000 cells,
corresponding to a yield of a few hundred MSCs/milliliter
of marrow), mesenchymal stem cells are easily expandable
through standard culture techniques. Upon cultivation, they
assume a spindly shaped morphology. MSC primary culture
has been reported to be heterogeneous, containing multi-
ple colonies with various differentiation capacities: nearly
one-third of these colonies have osteogenic, adipogenic,
and chondrogenic differentiation potentials, while the other
two thirds exhibit either bipotent or unipotent capacity to
differentiate into osteogenic/chondrogenic and adipogenic
lineages, respectively [15].
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Figure 2: Schematic representation of autologous chondrocyte implantation (ACI) procedures. First, chondrocytes are extracted
arthroscopically from the patient’s healthy articular cartilage (nonload-bearing area of either the intercondylar notch or the superior ridge
of the femoral condyles). Then, chondrocytes are expanded in vitro for approximately four to six weeks. Finally, once a sufficient number of
cells have been obtained, the patient undergoes a second surgery where the cultured and amplified chondrocytes are applied to the damaged
area. These transplanted cells grow in their new environment, forming new articular cartilage.
3.2. Other Sources of MSCs. Besides bone marrow, multiple
tissues have been reported to contain MSCs. These include
adipose tissue, trabecular bone, periosteum, synovial mem-
brane, and skeletal muscle, as well as teeth and umbilical
cord [16]. Furthermore, some researchers have paid special
attention to synovial membrane as a potent source of stem
cells with good chondrogenic potential.
Unlike bonemarrowMSCs, adiposeMSCs can be isolated
in large quantities with minimal morbidity and discomfort
[17, 18]. The frequency of MSCs in adipose tissue is in
the order of 1 in 100 cells, about 500-fold more than that
found in bone marrow [19]. In view of these practical
advantages, MSCs from adipose tissue could be considered
an alternative option for bone marrow MSCs in cell-based
cartilage regeneration strategies.
MSCs derived from synovial membranes also possess
multilineage potential. These cells can be stimulated to
undergo chondrogenesis in vitro with appropriate inducers.
A study by Shirasawa et al. [20] showed that human synovial-
derived cells have greater chondrogenic potential than bone
marrow MSCs, adipose MSCs, and periosteal- or muscle-
derived cells from the same patients. Furthermore, a follow-
up study by the same authors indicated that synovial-derived
MSCs produce consistently larger cartilage than bone mar-
row MSCs from the same patients [21].
In light of their availability, MSCs from skeletal mus-
cle are also attractive sources of cells for use in cartilage
tissue engineering because it is the largest organ in the
body and only a minimally invasive procedure is required
to harvest the tissue via muscle biopsy. Muscle has been
extensively investigated as a potential source for isolation
of pluripotent stem cells that can differentiate into various
lineages, including myogenic, hematopoietic, and osteogenic
[22, 23]. Concerning chondrogenic differentiation, it has been
reported that the use of mice muscle-derived stem cells
implantation to repair articular defects improved the healing
of the defect, by inducing hyaline cartilage formation with an
efficiency equivalent to chondrocyte transplantation [24–26].
Finally, another promising source of progenitor cells is
umbilical cord blood (CB), even if it contains heteroge-
neous populations of stromal cells. Nevertheless, they were
described as less mature than bone marrow MSCs and
therefore open larger potential in regenerative medicine.
Several subclinical or clinical trials are performed for now
in the field of cartilage therapy [27]. However, classification
of umbilical CB progenitor cells in subclasses is still uncom-
pleted and further isolation of new markers will help in
the characterization of the precise population that triggers
chondrogenesis.
4. Differentiation towards Chondrogenesis
Repair or regeneration of cartilage depends on several param-
eters. When used, adult stem cells trigger chondrogenesis
through a combination of events, including adaptation to a
hypoxic milieu and activation of Sox proteins pathway that
promote cells to produce their own cartilaginousmatrix (type
II collagen and aggrecan) [11]. Trophic factors are also of
importance in this process. Among them, TGF betamembers
are widely used according to their well-stated role in the
promotion of cartilage markers by MSC. However, it is likely
that they act by a specific and sequential manner as described
recently in a study that used a miRNA that regulates early
chondrogenesis [28, 29]. Hence, the role of miRNAs emerges
also as crucial in chondrogenesis and its elucidation will give
more accurate information in the process of chondrogenesis.
Finally, terminal differentiation is achieved by mechanical
loading as well as hydrodynamic pressure, known to activate
Sox-9 pathway and therefore chondrogenesis [30].
5. Culture Medium
The differentiation of adult stem cells into different cell types,
especially to produce cartilage tissue, is reliant on the local
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microenvironment, growth factors, and extracellular matrix
[31, 32].
Cell culture confers a highly controlled artificial envi-
ronment on cells that can greatly modify their behavior.
Classically, expansion protocols use a base medium, such as
Dulbecco’smodified eaglemedium (DMEM), containing 10%
fetal calf serum, maintained in a controlled 37∘C atmosphere
of 5% CO
2
and ambient oxygen (∼20%). Taking this to
represent baseline conditions, numerous attempts have been
made to modify the culture conditions in order to maintain
a more stem-like nature of the resulting cells or favor
chondrogenic differentiation.
A defined medium for in vitro chondrogenesis of MSCs
was first reported, in 1998, by Johnstone et al., who used
micromass culture with TGF-𝛽 and dexamethasone [32].
More recently, the necessity of cultured MSCs in medium
containing dexamethasone to induce chondrogenic differen-
tiation [33] and to add growth factors belonging to the TGF-
𝛽 superfamily that constitute the earliest signals in chon-
drogenic condensation [34] was reported. Thus, medium is
frequently supplemented with TGF-𝛽 superfamily members.
TGF-𝛽1 is an important growth factor in tissue engi-
neering for cartilage repair. It has been shown to promote
chondrocyte proliferation and differentiation, both of which
are important features of effective cartilage regeneration
[35]. TGF-𝛽 is also known to be a potent inducer of
stem cells chondrogenic differentiation and to favor the
differentiation of MSCs to form ectopic cartilage in vivo.
Supplementation with TGF-𝛽1 could initiate and promote
chondrogenesis of synovium-derived stem cell, but TGF-
𝛽1 alone was insufficient to fully differentiate these cells
into chondrocytes. In muscle stem cells, our group also
confirms the importance of TGF-𝛽1 not only in enhancing the
chondrogenesis, but also in maintaining the chondrogenic
phenotype. In these stem cells, we showed that TGF-𝛽1
enhances GAGs deposition, aggrecan, and type II collagen
synthesis. Moreover, type I and type X collagen syntheses
were inhibited, particularly in CD56−cells, suggesting that
chondrocytes did not demonstrate significant hypertrophy.
This data was further supported by the inhibition of nuclear
proteins binding activity on Cbfa1 consensus sequence in
TGF-𝛽1-treated muscle stem cells, which could explain TGF-
𝛽1-induced downregulation of type I and type X collagens
expressions [26]. TGF-𝛽1 has also been shown to inhibit
terminal differentiation of chondrocytes [36, 37].
However, findings concerning TGF-𝛽1 effect on MSCs
are still controversy and underline the fact that its effect
on osteoblastic or chondrogenic differentiation of MSCs
depends on culture conditions and doses used. In vitro exper-
iments demonstrated that its use may lead to hypertrophic
differentiation, with subsequent formation of an inadequate
tissue instead of hyaline cartilage [38, 39]. In addition, a
high dose of TGF-𝛽1 via intra-articular injection is known
to induce chemotaxis and activation of inflammatory cells,
resulting in characteristic cartilage defects such as fibrosis
and osteophyte formation [35]. Therefore, it is evident that
TGF-𝛽1 should be administered in a controlled manner to
minimize adverse effects.
Several other growth factors are known to influence the
anabolic and catabolic processes of chondrocytes. Therefore,
a number of these growth factors have been used in cartilage
tissue engineering studies in vitro to promote the chon-
drogenic phenotype, to stimulate extracellular matrix pro-
duction, and to promote chondrogenesis of MSCs. Among
others, TGF𝛽-3 stimulates the synthesis of proteoglycans
and collagens matrix components [40] and is necessary for
different steps during chondrogenesis. It probably acts by
inducing the expression of Sry-related high-mobility-group
box-9 (Sox-9) [41], which in turn regulates the expression of
aggrecan and collagen type II, type IX, and type XI during
chondrocyte differentiation.
Furthermore, research has indicated that addition of bone
morphogenetic proteins (BMPs) also enhances chondroge-
nesis and can be used for the development of cartilage
engineering strategy. BMPs have multiple important roles
during skeletal formation [35]. BMP-2, -5, and -6 maintain
and promote later stages of chondrocyte differentiation rather
than initiation ofmaturation [42], while BMP-7 (also referred
to as osteogenic protein 1, OP-1) promoted chondrocyte pro-
liferation and inhibited terminal differentiation [43]. BMP-2
also regulates the chondrogenic differentiation and the
maturation of mesenchymal progenitors and stimulates the
synthesis of chondrocyte matrix components, [44]. For this
reason, BMP-2 has been proposed as a tool for cartilage repair
and as an inducer of chondrogenesis.
In cultures of human mesenchymal stem cells, BMP-2
as well as BMP-9 increases the synthesis of cartilage-specific
proteins [35]. Comparing the ability of BMP-2, BMP-4, and
BMP-6 to promote the differentiation of mesenchymal stem
cells from bone marrow toward chondrocyte showed that
BMP-2 appears to be the most effective. However, under
BMP-2, mesenchymal stem cells can possibly continue their
differentiation to hypertrophy and osteogenesis, character-
ized by type X collagen and Runx2 expression. Finding a
way to reduce this adverse effect is subsequently essential to
the development of an efficient strategy of tissue engineering
for cartilage repair. Some researchers propose to cotreat
cells with TGF-𝛽 and BMP-2. Pretreatment with TGF-𝛽
could prevent fully differentiation of MSCs into osteoblasts
[45]. Although BMP-2 induces osteogenic and chondrogenic
phenotypes in adipose-derived stem cells, TGF-𝛽1 can inhibit
BMP-2-induced differentiation of the osteogenic lineage, and
combined growth factor treatment shows a synergistic effect
on the expression of cartilage-specific genes and elevated
release of cartilage-specific ECM proteins [46].
GDF-5 (growth differentiation factor-5) also known
as BMP-14 or cartilage-derived morphogenetic protein
(CDMP-1) shows also some capacity to stimulate cartilage
matrix synthesis. It induces the differentiation of mesenchy-
mal stem cells into chondrocytes and promoted increased
accumulation of GAG and type II collagen during pellet
culture [47].
Other cytokines, such as insulin-like growth factor (IGF),
or parathyroid hormone related peptide (PTHrP) had been
tried for better differentiation of stem cells, but it is still
difficult to obtain “in vitro” MSC-based cartilage formation
comparative to native cartilage tissue [32].
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Figure 3: Schematic representation of cell therapy for cartilage based on stem cell implantation. Mesenchymal stem cells (MSCs) are isolated
from different sources: bone marrow, fat tissues, or umbilical cord. Synovial-derived cells or MSCs derived from skeletal muscle can also be
used. Then, these cells are either injected into damaged zone of cartilage or amplified in vitro. After amplification, stem cells are injected into
damaged cartilage directly or after a stage of activation toward chondrogenesis by addition of growth factors, cultured in hypoxia and in an
adapted scaffold.
6. Biomaterials and Scaffolds
As evidenced by previous paragraph, growth factors are
essential to induce chondrogenic differentiation of adult stem
cells. However, to promote/maintain cartilage differentia-
tion/phenotype in culture, another critical requirement is
to provide a 3D microenvironment. Indeed, research has
demonstrated that MSCs hardly differentiate into cartilage
cell lineage in a 2D culture system.
The initial technique for chondrogenic differentiation of
MSCs was the micromass culture system. The cells were
placed in a tube and centrifuged into a condensed aggregate.
To date, this technique is still widely used to evaluate
chondrogenic potential of MSCs in vitro. MSCs cultured in
micromass increase expression of type II collagen, amarker of
chondrocyte phenotype, but they also increase the expression
of hypertrophic marker, such as type X collagen [32].
For applications of cartilage tissue replacement, most
investigators preferred transplantation of cells combinedwith
scaffold. So, a huge expansion in biomaterial technologies and
scaffolds took place to create functional tissue replacement
to treat cartilage defects or osteoarthritis. Numerous bioma-
terials and scaffolds are being developed, influenced by the
knowledge of the anatomical and structural complexity of
articular cartilage. In addition to being biocompatible and
accommodating cell adhesion, proliferation, and matrix syn-
thesis, an ideal biomaterial scaffold for cartilage regeneration
should be bioactive, biomimetic, biodegradable, and biore-
sponsive, providing signaling with spatiotemporal control
and response that is selective to defined stimuli.
Natural and synthetic scaffolds have been developed.
Natural materials, such as collagen, hyaluronic acid, or
alginate, have advantage to be biodegradable, easily available,
and bioactive. For their part, synthetic materials, such as
polyethylene glycol (PEG), polyglycolic acid (PGA), poly-
methyl methacrylate (PMMA), or polylactide-co-glycolide
(PLGA), are inert and have a long shelf-life. Their physical
proprieties can also be easily changed (porosity, degradation
time. . .) [9].
7. Clinical Trials
Many clinical trials have been registered at https://www
.clinicaltrial.gov/ regarding application of stem cells for
regenerating cartilage. About 40 studies (phase 1 to 3) are in
progress or are completed worldwide (Table 1). Most of them
aim to repair cartilage defects or treat degenerative damage,
in knee, ankle, or hip, due to osteoarthritis. One clinical trial
aims to implant a partial larynx.
Different strategies are tested (Figure 3). The simplest
and most frequent one consists of intra-articular injection of
mesenchymal stem cells, either directly after collection (i.e.,
fresh non cultured and expanded cells), or after amplification
and culture during 2–4 weeks. Another strategy aims to
mix stem cells with a scaffold for implantation. For this,
different biomaterials are testing collagen hydroxylapatite
scaffold, collagen I scaffold, or decellularized human donor
scaffolds. Three sources of stem cells are used: bone marrow-
derived mesenchymal stem cells, adipose-derived stem cells,
and umbilical cord blood-derived mesenchymal stem cells.
Some preliminary results have been published and
are promising. A 31-year-old male patient having received
MSC/collagen gel into cartilage defects in his knee returned
to a normal life seven months after implantation and the
formation of hyaline cartilage in the histological sections
has been observed [48]. Similarly, Wakitani et al. trans-
planted autologous MSCs combined with collagen gel into
five patients with full thickness articular cartilage defects in
their patellofemoral joints and observed significant improve-
ments in patients’ pain and walking ability six months after
transplantation. However, one year after transplantation,
histological examination of the repair tissue from one patient
revealed that the defect was repaired by fibrocartilaginous
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tissue [49, 50]. The same group made also some attempts
to treat osteoarthritic joints. In these clinical trials, adher-
ent cells from bone marrow aspirates were embedded in
collagen gel and transplanted into articular cartilage defects
in the medial femoral condyle of 12 patients, while the
other 12 subjects served as cell-free controls. Outcomes
indicated that although clinical improvement was not sig-
nificantly different, the treatment group showed a better
arthroscopic and histological grading score [51]. In the above-
mentioned study, MSCs were introduced through an invasive
approach (surgery) into the defective area. Some authors
have attempted to introduce the cells by injection. Using
this approach, Centeno et al. [52] applied culture expanded
autologousMSCs and transplanted the cells through an intra-
articular injection into the knee of a 46-year-old OA patient.
They reported that 90% of the patient’s pain was reduced
two years after injection. Furthermore, Davatchi et al. [53],
Emadedin et al. [54], and Orozco et al. [55, 56] used this
strategy to introduce the cells into knee joints of OA patients
and reported the strategy as an encouraging method.
8. Pitfalls and Future Developments
In spite of the above-mentioned potential, there are some
pitfalls associatedwithMSC application for articular cartilage
regeneration. One is the qualities and mechanic properties
of neoformed cartilage, and the second is the fabrication of
anatomically relevant 3D engineered tissue and its integration
into surrounding native joint tissues.
8.1. Improving Quality of Cartilage Implant. Quality of car-
tilage obtained after implantation of stem cells in joints is a
major issue. Indeed, it has been reported that the thickness of
the regenerated cartilage byMSCs transplanted into cartilage
defects is too thin to resemble mature cartilage [57], and
histological examination of the repair tissue from patients
revealed that the defect was repaired by fibrocartilaginous
tissue. A fear is also the risk of ossification of cartilage tissue
[58–61]. Another major limitation for clinical applications is
the presence of serum and growth factors in chondrogenic
medium to induce chondrocyte phenotype, what raises cost
of protocols and causes important ethic and regulation
problems.
Amajor improvement of current methods to differentiate
stem cells into chondrocytes will be developing culture
conditions which will require neither serum nor growth
factors. Several investigators, including us, have exploited low
oxygen tension as a strategy for differentiated stem cells into
chondrocytes. These studies have shown that hypoxia (1–3%
O
2
) enhances COL2A1 and aggrecan expression and reduces
expression of collagen types I and X [11]. Interestingly, 3D
culture (alginate beads) associatedwith hypoxic environment
is sufficient to differentiate human bone marrow-derived
mesenchymal stem cells into chondrocytes, without addition
of any growth factor [11].
Furthermore, gene therapy approaches could become a
promising strategy for efficient promotion of regeneration
in cartilage defects. MSC-based gene therapy offers some
advantages for articular cartilage repair. Using this approach,
specific genes could be overexpressed in MSCs before trans-
plantation of these modified cells into articular cartilage
defect. This in turn could enhance the structural features
of the repair tissue formed at the defect site. Furthermore,
MSC-based gene therapy is an applicable approach to deliver
genes with complementary mechanisms of action (i.e., chon-
drogenic and proliferative factors) into a cartilage defect. In
many studies, MSC-mediated gene delivery has been applied
for cartilage repair using a variety of chondrogenic growth
factors, such as IGF-1, TGF-𝛽1 or BMP-2 [62–65], BMP-4
[25], and growth differentiation factor 5 [66].
Another way to improve cartilage engineering is to use
other sources of stem cells. A recent evolution consists of
studying potential of induced pluripotent stem cells (iPSCs)
to differentiate in chondrocytes. iPSCs have pluripotency and
self-renewal similar to embryonic stem cells (ESCs) but are
not associated with the ethical issues related to sacrificing
embryos for the generation of ESCs. The iPSCs were first
generated, in 2006, by transducing mouse fibroblasts with
four factors (c-Myc, Klf4, Oct3/4, and Sox-2), called repro-
gramming factors [65]. The efficiency of iPSC generation has
been greatly improved since its initial discovery. Blood cells
can also be converted to iPSCs [67], although the efficiency
is lower than that associated with generating iPSCs from
fibroblasts. When iPSCs are implanted into immunodeficient
mice, teratomas are formed. Interestingly, hyaline cartilage
is contained in these teratomas, confirming that iPSCs
have the ability to differentiate into chondrocytes. Various
approaches have been developed to induce the differentiation
of iPSCs toward chondrocytes [68]. As a whole, the reports
on these methods showed that the resultant cells expressed
chondrocytic markers but rarely showed that the resultant
cells could actually generate scaffold-free hyaline cartilage. It
remains to be proven that chondrocytes differentiated from
human iPSCs can definitely generate cartilage with the same
characteristics as native tissue. In addition, the use of iPSCs
is associated with a potential risk of tumor formation. How-
ever, several studies have implanted human iPSC-derived
chondrocytes into immunosuppressed rats [69]. Cartilage
was formed in the defects created in the articular cartilage
of these rats, without any teratoma or tumor formation,
suggesting that iPSC-derived chondrocytes are a promising
source of cells for transplantation. The efficacy and safety
of such transplantation remain to be investigated in more
immunodeficient animals and larger animal models which
would allow for a more accurate assessment of the repair
capacity of the cells.
8.2. Improving Anatomy and Zonal Organization of Neo-
formed Cartilage. Another challenge in cartilage engineering
approaches is the generation of cell-seeded implants with
structures that mimic native tissue, in both anatomic geome-
tries and cellular distributions [70]. The ideal implanted
tissue should integrate with existing native cartilage and
be able to repair lesions of different sizes and thicknesses.
Existing processes are incapable of easily creating cartilage
responding to these criteria, that is, with the required spatial
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heterogeneities and accurate anatomical geometries. Three-
dimensional bioprinting should solve this difficulty in the
next years. This technology consists in delivering living
cells in suspension or with a gel as an ink, in layer-by-
layer process. It should allow bringing cells with appropriate
matrix material in a defined and organized manner, at the
targeted location, in adequate numbers and within the right
environment.One of themost critical challenges for use of 3D
printing for tissue engineering is the integration of a vascular
network, without which the engineered 3D tissue or organ
cannot receive sufficient nutrients or gas for its regeneration
[71]. However, cartilage has a relatively simple structure with
no vessels or nerves, making cartilage a suitable tissue for 3D
bioprinting.
Inkjet printing [72, 73], laser-based direct writing of cells
[74–76], and extrusion-based cell-laden hydrogel deposition
[77–79] are the most widely used technologies in develop-
ment for tissue reconstruction.With these technologies, cells,
scaffolds, and growth factors can be precisely deposited to the
desired two-dimensional (2D) and three-dimensional (3D)
locations rapidly. The bioprinting approach often utilizes
naturally derived hydrogels, as inks to construct tissues due
to their superior biocompatibility and low toxicity on the
cells. For instance, collagen scaffold can be printed at 4∘C and
physically crosslinked at elevated temperature [80]. Alginate
[72] and fibrin [81, 82] scaffolds can also be generated
and used to print cells. For example, cartilage progenitor
cells encapsulated in sodium alginate and printing through
a pressure-assisted robotic bioprinting system are able to
survive after bioprinting and to undergo differentiation with
high-level cartilage-associated gene expression. However,
some cells died probably due to mechanical stimulation
during bioprinting [83]. These natural printed scaffolds have
limited mechanical properties because of their nature, and
the crucial phenomenon of integration with surrounding
native tissues directly may be difficult. Therefore, devel-
oping of printable biomaterials, capable of simultaneous
polymerization during printing with mechanical properties
matched to native tissue, is critical for cartilage engineering.
Synthetic hydrogels may be adapted. Thus, formulated from
poly(ethylene glycol) (PEG) macromers are able to maintain
chondrocyte viability and induce ECMdeposition containing
proteoglycans and type II collagen [84, 85]. Furthermore,
polyethylene glycol dimethacrylate (PEGDMA) with human
chondrocytes was also used to repair defect in osteochondral
plugs in layer-by-layer assembly utilizing a 3D thermal inkjet-
based bioprinting/biopolymerization method. Viability of
printed cells was better in simultaneous polymerization than
polymerized after printing. Interestingly, the printed PEG
gel was firmly bound to the native tissue [86]. Despite its
ability to control the scaffold porosity, the synthetic scaffold
may not provide the proper affinitive environment to the
cells due to the polymer hydrophobicity properties. In this
context, hybrid scaffolds using both synthetic polymers and
hydrogel materials may also provide a favorable environment
within the hydrogel for the cells to grow and can possessmore
adequate mechanical properties permitting implants to bear
loads [87].
9. Conclusion
Although initially considered as a tissue with a simple
structure, reproducing the finely balanced structural inter-
actions of cartilage has proven to be difficult. First clinical
trials of cartilage regeneration using autologous chondrocyte
implantation chondrocyte showmajor limits. In this context,
adult stem cells, especially MSCs, appear as more appropriate
cell candidates for regenerating incurable defects of articular
cartilage due to the following characteristics: inherent chon-
drogenic property, easy availability, cell homing potential,
and immunomodulatory function. However, special atten-
tion must be given to improve the quality of repair tissue
formed following stem cells transplantation into the cartilage
defect. Efficient protocols and optimal biomaterials must be
developed to prevent hypertrophy of chondrocytes produced
by MSC differentiation and to favour integration of implant
into surrounding joint tissue. In addition, bioprinting tech-
nology, which has advantage to deliver cells, growth factors,
and biomaterial scaffold precisely to the desired 3D position,
may be the ultimate solution to engineer cartilage tissue.
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